The FDA-approved EGFR monoclonal antibody cetuximab has been combined with chemotherapy or radiotherapy as a first-line therapy for HNSCC patients, but the acquisition of EGRF resistance was a frequent occurrence, eventually leading to therapy failure. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.